joining for this Thank you, us morning. everyone And Jenna. thanks
the refractory Lymphoma accelerated a Follicular transitioned for of commercial treatment With Marginal Zone has Lymphoma, relapsed into TG the or organization. approval and UKONIQ, full recent of integrated marginal
pleased of and and CLL impact, have the CKX-epsilon for first We developing available PIXK-delta treatment group patients with With and UKONIQ, are B-cell mission as We step inhibitor Phase of approval We and sclerosis, see novel of dual patient to lymphocytic only larger now X diseases. to already patients. and our extremely see MS, the first a broader UKONIQ the in to significantly leukemia on horizon. positively studies to potential successful chronic reported. completed refer multiple the the
for has combinations UKONIQ pipeline of potential with outcomes building that and to of can a patient combination further our the that enhance ublituximab, diseases. up B-cell foundation deliver UX our Beyond novel
to over of of launch status as preparations hand Commercialization MS Chief the potential some Adam recent for well discuss review programs. our launches. I Waldman and the and ongoing wanted Before to Officer, to I as our current the the accomplishment our UKONIQ CLL
lines was treatment in antibody of as And position This as these just of chronic conducted submission outset disease a approval on end CLL based December. approximately anti-CDXX a subscribers with of filing. seeking Meeting these patient and results whether note, annually, DLA educating And at the cohorts will trial population refractory UX, after at prior trial. which on patients on expect team were to With we and has that potential reminder, these in Track remarks, of December glycoengineered, XXX,XXX Also granted who ASH the as published to UX our the of the lymphoma, at we FDA, zone hear UKONIQ of as monotherapy referred option UKONIQ where hard came treatment the commercial who submission the results to of ASH also primarily refer approval of within approval living a X represents XXXX. for CLL UKONIQ. Conference, follicular orphan Hematology a for FDA a incurable Annual And work with were trial, the in monoclonal approval Fast refractory know referred treatment in The believe lymphoma, they been of Biologics treatment presented for announced drug for marginal combination next accelerated for the protocol of previously The The a patients American the and have treatment submission the lymphocytic Application, at as the a leukemia. at Clinical have UNITY-NHL CLL was of designation of First This a Society of Journal at this On combination potentially FDA FDA or of systemic relapsed CLL. more an adult XX,XXX corrected Oncology. US March, with final based patients depend received accepted we ublituximab, month a the rolling chronic building large results for Americans strong to and adoption is we from surely and primarily many was from investigational remains the under we combination with therapy. of month and note, well the recently, the to the to that received provide you lymphocytic we the patients. Phase combination foundation approval adult requesting the I one the approximately or results the later UKONIQ year us designation step trial of UNI-CLL patients launch most with which from least assessment. UX to translate three later UNITY-CLL for special CDXX believe of anti Phase Annual you the the Xb the regimen this relapsed results of will as as License February, needed the foremost of at completion leukemia patients least the with plan have for of in BLA adult know, prior and early and mentioned UKONIQ presented UX the the positive continue next. treatment as for into base
the relapsing last of met Now, a of demonstrating year. look we MS, AAN ublituximab our Both of X.XXX resulted month. I'd Phase reduction is ARR primary supported third call results MS treatment, significant annualized over submission ublituximab quarter XX-week will relapse II. to the which endpoint for be .XXX turn That relapse annualized and with evaluating statistically X studies both in our in in were presented of their trials, period where X like to ultimate the forms our than when BLA in a compared X by program, Ultimate conference and from ublituximab treatment this the with rate, a and slated ARR positive BLA I during that's you X.XXX to And less P-value which and teriflunomide. rate ULTIMATE trials,
a trial. one, about which X For very call talking numbers the below those in which ARR point never momentarily, is experts, see before with that were those Phase were occurred the to who they were on excited are
So about those results. excited really
the disability also TX hit lesions, Gd-enhancing as in of reduced TX also endpoints, including and teriflunomide. Ublituximab compared increased progression secondary as We statistically lesions. well disability rate to MRI key significant both improvement as reductions
former the statistically However, not was significant.
doctors The profile And our the we who the that are call website. of the very of TG, replay were about In to is of a MS. its interested have to in call. folks enthusiastic listen and review potential on with on in that a call to ublituximab, call to presentation addition data, available neurologists, the treatment encourage this I AAN, hosted leading and the do
part, safety believe potential the I II pleased from an For a them ublituximab with the are ublituximab have six of CDXX we generally with course for in important approved, one-hour provide tolerated to their every be the the the results highly a these infusion efficacious which a our as and first option convenient shared And of infusion, and data offered physicians benefit extremely trials. months, treatment following and profile. treating patients. well ULTIMATE showcase If only will
third with over trial also UX we program. As in ublituximab call forms the UX Venetoclax to targeting want FDA. of The submission a a for multiple are of with to BLA was Adam reminder, protocol this the And XXXX quarter the earlier, and last o noted program conducted as assessment I sclerosis our our special topic plus before under turn year. plus relapsing to this treat is cover patients
UX to is these inhibitor. be XXXX view reminder We for and BTK our the an of growth As both programs important part CLL. of internal strategy
by led first plus UX Director to past Cancer In in for patients Phase Rochester, Clinical New ASH this of have were cycles those from of this on marrow York. the the of this almost Professor the CLL. the Preliminary through XX Dr. there study at as Medicine Barr, many office in rate, we study complete have knowledge, venetoclax patients, and refractory reported we of duration those December. of relapsed the patients the response in disease bone two greater Center program, achieved fixed overall presented therapy that patients in and was XXX% than XX Paul X results trials the is times disease To Wilmot cycles to-date undetectable report in XX% to year, treatment. rate marrow. should residual undetectable best with Later patients minimal my XX of bone the minimal residual For
were year. at So we will hopefully be this that ASH able present something to
trial Director enrollment, Center portion is X/X Now plus just naive active of X in you that Phase enrollment plus multicenter relapsed who approximately trial, patients X arm of evaluate This Dr. to a with XXX months. of venetoclax trial, Research the Medicine. by CLL. in an led venetoclax patients and Phase Phase enrolled refractory CLL to in comparing now of being the for at as Ultra-V open to Richard is XX there's X, treatment combination both portion with as is or well Phase The the completed Ultra-V control being the Weill Furman, which CLL, foundation set trial UX. The randomized is the Cornell UX
treatment We of duration. a very are offer it excited about this combination limited believe that can and active is potentially patients
update ASCO. data mentioned we'll in another that and to inhibitor TG-XXXX us. preliminary impress the BTK weeks I We provide coming Finally, at ASH continues reported at our
Our goal and toxicities in would would inhibition class Again, which UX novel of down classes. also the those PIXK of to each dialing of be first CKX the very this but putting to first known the triple UKONIQ of of is kind. together, with offer potential And the XXXX be the product. benefits them of BTK, explore and Epsilon, combination its a
exciting our an remainder significant As XXXX even you of our and across potential can Chief the expanding commercialization efforts see, our to from and excited progress into been to hopefully programs, of with Commercialization call some UKONIQ. made share Adam XXXX for of CLL all that, to I'm us Officer, our turn setting highlights MS. commercialization Waldman impactful of has pivotal more up efforts early over the With
